Alnylam Pharmaceuticals
ALNY
#646
Rank
A$48.35 B
Marketcap
$374.93
Share price
-0.77%
Change (1 day)
51.45%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : A$1.99 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is A$1.99 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$1.91 B-1.24%
2022-12-31A$1.94 B40.99%
2021-12-31A$1.37 B103.01%
2020-12-31A$0.67 B56.2%
2019-12-31A$0.43 B919.01%
2018-12-31A$42.58 M10.82%
2017-12-31A$38.42 M-81.53%
2016-12-31A$0.20 B
2007-12-31A$7.72 M-33.3%
2006-12-31A$11.58 M14.67%
2005-12-31A$10.1 M8.61%
2004-12-31A$9.3 M272.07%
2003-12-31A$2.5 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$0.18 B-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
A$4.13 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.13 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.41 B-79.30%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.03 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
A$49.23 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$38.98 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
A$29.51 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel